

Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update – ERRATUM

Paul W. O'Connor, Marcelo Kremenchutzky

doi:10.1017/cjn.2015.400

Can J Neurol Sci. 2017; 44: 467

doi:<http://dx.doi.org/10.1017/cjn.2015.296>, Published by Cambridge University Press, 27 October 2015.

“Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update” by O'Connor & Kremenchutzky published with an error in the second paragraph under the section subheading “*Update on efficacy and safety evidence with natalizumab in MS*”, stating that “The multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetazel-Based Chemotherapy (AFFIRM)...”

The corrected sentence should read:

“The multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Natalizumab in Patients with Relapsing Multiple Sclerosis (AFFIRM)...”

We sincerely apologize for this error.

REFERENCE

1. O'Connor P, Kremenchutzky M. Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update. *Can J Neurol Sci.* 2015;42:372-80. (doi:<http://dx.doi.org/10.1017/cjn.2015.296>).